Advances in cancer immunotherapy development: VHH-based immune checkpoint inhibitors targeting the receptor ILT4
ILT4 (immunoglobulin-Like Transcript 4) is an immune checkpoint receptor mainly expressed by myeloid immune cells. In cancer context, ILT4 participates in tumor development by maintaining a pro-tumoral immuno-microenvironment and directly promoting tumor cell proliferation. […]
CORONABODIES : Production of SARS-CoV-2 nucleoprotein (N) and spike (S) recombinant antigens and generation of anti-N and anti-S nanobodies for diagnostic and therapeutic applications. SUMMARY We propose a joint effort to generate as […]
VenoMATIcs: Toward a Global Management of Venoms and Envenomations: the Pasteur network Translational Approach
VenoMATIcs’ project aims to strengthen collaborations between Institut Pasteur academic research partners based in 4 MATI regional countries (Morocco, Algeria, Tunisia, Iran), 3 research teams from Institut Pasteur of Paris, in order to use […]
2022Development of a highly specific and sensitive VHH-based sandwich immunoassay for the detection of the SARS-CoV-2 nucleoprotein., J Biol Chem 2022 Jan; 298(1): 101290.
2020Single-domain antibodies targeting antithrombin reduce bleeding in hemophilic mice with or without inhibitors., EMBO Mol Med 2020 Apr; 12(4): e11298.
2018A factor VIII-nanobody fusion protein forming an ultrastable complex with VWF: effect on clearance and antibody formation., Blood 2018 Sep; 132(11): 1193-1197.
2018Macrophage scavenger receptor SR-AI contributes to the clearance of von Willebrand factor., Haematologica 2018 Apr; 103(4): 728-737.
2017A Novel Single-Domain Antibody Against von Willebrand Factor A1 Domain Resolves Leukocyte Recruitment and Vascular Leakage During Inflammation-Brief Report., Arterioscler Thromb Vasc Biol 2017 Sep; 37(9): 1736-1740.
2017Complex formation with pentraxin-2 regulates factor X plasma levels and macrophage interactions., Blood 2017 Apr; 129(17): 2443-2454.
2016LIM kinase/cofilin dysregulation promotes macrothrombocytopenia in severe von Willebrand disease-type 2B., JCI Insight 2016 Oct; 1(16): e88643.